Active, not recruitingPhase 1NCT06433531
A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP)
Studying DITRA
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Intervention
- TQH2929 Injection(drug)
- Enrollment
- 9 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2024 – 2025
Study locations (7)
- Peking University First Hospital, Beijing, Beijing Municipality, China
- Dermatology Hospital of Southern Medical Universitye, Guangzhou, Guangdong, China
- The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
- The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
- The First Hospital of China Medical University, Shenyang, Liaoning, China
- Second People's Hospital of Chengdu, Chengdu, Sichuan, China
- The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06433531 on ClinicalTrials.govOther trials for DITRA
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07552454Picankibart in Palmoplantar PustulosisXijing Hospital
- RECRUITINGPHASE2NCT07314060A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular PsoriasisChia Tai Tianqing Pharmaceutical Group Co., Ltd.
- ACTIVE NOT RECRUITINGNCT06952465A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With PsoriasisBristol-Myers Squibb
- RECRUITINGPHASE2, PHASE3NCT06477536Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular PsoriasisShanghai Huaota Biopharmaceutical Co., Ltd.
- ACTIVE NOT RECRUITINGPHASE3NCT06323356A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic PsoriasisTakeda
- ACTIVE NOT RECRUITINGPHASE3NCT06295692A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic PsoriasisJanssen Pharmaceutical K.K.
- ACTIVE NOT RECRUITINGPHASE4NCT06013969A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated FlaresBoehringer Ingelheim
- RECRUITINGNCT06100991CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness RegistryCorEvitas